

Kayo Tanaka

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6402206/kayo-tanaka-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	64 citations	5 h-index	8 g-index
20 ext. papers	105 ext. citations	3.4 avg, IF	1.62 L-index

#	Paper	IF	Citations
14	Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice. <i>American Journal of Hypertension</i> , 2017 , 31, 89-96	2.3	19
13	Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 521, 769-774	3.4	12
12	Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
11	Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions. <i>Scientific Reports</i> , 2019 , 9, 234	4.9	7
10	TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. <i>BMJ Open</i> , 2018 , 8, e020948	3	5
9	Tadalafil treatment for preeclampsia (medication in preeclampsia; MIE): a multicenter phase II clinical trial. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 34, 3709-3715	2	4
8	Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy. <i>Case Reports in Obstetrics and Gynecology</i> , 2019 , 2019, 4290145	0.8	2
7	Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	2
6	Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019 , 32, 2460-2462	2	2
5	Phase-1 clinical study of tadalafil administered for selective fetal growth restriction in twin pregnancy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 34, 1075-1082	2	0
4	A Case of Bursitis Presenting with a Xanthogranuloma like Histology in a Patient with Collagen Disease. <i>Nishinihon Journal of Dermatology</i> , 2020 , 82, 90-93	0	
3	A Case of Prepubertal Unilateral Fibrous Hyperplasia of the Labium Majus. <i>Nishinihon Journal of Dermatology</i> , 2019 , 81, 293-296	0	
2	Placental growth factor level is correlated with intrapartum fetal heart rate findings.. <i>BMC Pregnancy and Childbirth</i> , 2022 , 22, 215	3.2	
1	Assessment of the value of measuring soluble fms-like tyrosine kinase-1 and placental growth factor levels following administration of tadalafil to treat fetal growth restriction.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 1-5	2	